Access Type

Open Access

Presentation Type

Oral Presentation

Start Date

April 2017

End Date

April 2017

Department

Public Health

Abstract

Abstract

The brand name Botox was first assigned to a batch of botulinum toxin serotype A by Stanley Fahn, internationally avowed Doctor of Medicine and member of the Psychopharmacology Advisory Committee for the Food and Drug Administration (Erbguth, 2009; Fahn, 2016). Botulinum toxin is classified as one of the most potent toxic substances in the world. Efficacy for the therapeutic use of botulinum toxin is based upon the premise that botulinum toxin remains in the peripheral nervous system and is incapable of breaching the Blood-Brain Barrier (Tenenbaum, 2016). Since receiving initial approval in 1989 botulinum toxin serotype A now also provides short term therapeutic treatment to manage various dermatological, muscular, and chronic pain diseases and disorders (Samuels, Correa, 2016). Allergan reveals that the greatest population at risk for botulinum toxin diffusion are children treated for muscle spasticity (Allergan Pharmaceuticals, 2016). Study Objective: To assess the severity of Off-Label Botox usage to treat children. Design: Meta-analysis of 165 children treated with onabotulinumtoxin A to manage spasticity and sialorrhoea. Methods and Measurements: The adverse events of 424 patients was assessed in excel and SPSS. Conclusion: 75 percent of patients experienced adverse events.

Keywords: onabotulinumtoxinA, Botox for Pediatrics, onabotulinumtoxinA for cerebral palsy

Faculty Mentor

Charlotte Guynes, Beth McKinney, Jennifer Hall, Tonya Price

Rights Statement

The right to download or print any portion of this material is granted by the copyright owner only for personal or educational use. The author/creator retains all proprietary rights, including copyright ownership. Any editing, other reproduction or other use of this material by any means requires the express written permission of the copyright owner. Except as provided above, or for any other use that is allowed by fair use (Title 17, §107 U.S.C.), you may not reproduce, republish, post, transmit or distribute any material from this web site in any physical or digital form without the permission of the copyright owner of the material.

Share

COinS
 
Apr 5th, 10:30 AM Apr 5th, 10:45 AM

Botox OnabotulinumtoxinA: Meta-analysis of the severity of off-label Botox use in Children with Cerebral Palsy

Abstract

The brand name Botox was first assigned to a batch of botulinum toxin serotype A by Stanley Fahn, internationally avowed Doctor of Medicine and member of the Psychopharmacology Advisory Committee for the Food and Drug Administration (Erbguth, 2009; Fahn, 2016). Botulinum toxin is classified as one of the most potent toxic substances in the world. Efficacy for the therapeutic use of botulinum toxin is based upon the premise that botulinum toxin remains in the peripheral nervous system and is incapable of breaching the Blood-Brain Barrier (Tenenbaum, 2016). Since receiving initial approval in 1989 botulinum toxin serotype A now also provides short term therapeutic treatment to manage various dermatological, muscular, and chronic pain diseases and disorders (Samuels, Correa, 2016). Allergan reveals that the greatest population at risk for botulinum toxin diffusion are children treated for muscle spasticity (Allergan Pharmaceuticals, 2016). Study Objective: To assess the severity of Off-Label Botox usage to treat children. Design: Meta-analysis of 165 children treated with onabotulinumtoxin A to manage spasticity and sialorrhoea. Methods and Measurements: The adverse events of 424 patients was assessed in excel and SPSS. Conclusion: 75 percent of patients experienced adverse events.

Keywords: onabotulinumtoxinA, Botox for Pediatrics, onabotulinumtoxinA for cerebral palsy